







RESEARCH PAPER



DNA methylation in promoter regions of genes involved in the reproductive and metabolic function of children born to women with PCOS

Bárbara Echiburú ^a, Fermín Milagro ^{b,c}, Nicolás Crisosto ^{a,d}, Francisco Pérez-Bravo ^e, Cristian Flores^a, Ana Arpón ^b, Francisca Salas-Pérez^b, Sergio E. Recabarren^f, Teresa Sir-Petermann^a, and Manuel Maliqueo ^a

^aEndocrinology and Metabolism Laboratory, West Division, School of Medicine, University of Chile, Santiago, Chile; ^bDepartment of Nutrition, Food Science and Physiology, Center for Nutrition Research, University of Navarra, Pamplona, Spain; ^cCentro De Investigación Biomédica En Red Fisiopatología De La Obesidad Y Nutrición (Ciberobn), Instituto De Salud Carlos III, Madrid, Spain; ^dUnit of Endocrinology, Clínica Las, Santiago, Chile; ^eLaboratory of Nutritional Genomics, Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile; ^fLaboratory of Animal Physiology and Endocrinology, Department of Animal Science, Faculty of Veterinary Sciences, University of Concepcion, Chillán, Chile

ABSTRACT

Clinical and experimental evidences indicate that epigenetic modifications induced by the prenatal environment are related to metabolic and reproductive derangements in polycystic ovary syndrome (PCOS). Alterations in the leptin and adiponectin systems, androgen signalling and antimüllerian hormone (AMH) levels have been observed in PCOS women and in their offspring. Using a targeted Next-Generation Sequencing (NGS), we studied DNA methylation in promoter regions of the leptin (*LEP*), leptin receptor (*LEPR*), adiponectin (*ADIPOQ*), adiponectin receptor 1 and 2 (*ADIPOR1* and *ADIPOR2*), *AMH* and androgen receptor (*AR*) genes in 24 sons and daughters of women with PCOS (12 treated with metformin during pregnancy) and 24 children born to non-PCOS women during early infancy (2–3 months of age). Genomic DNA was extracted from whole blood, bisulphite converted and sequenced by NGS. Girls showed differences between groups in 1 CpG site of *LEPR*, 2 of *LEP*, 1 of *ADIPOR2* and 2 of *AR*. Boys showed differences in 5 CpG sites of *LEP*, 3 of *AMH* and 9 of *AR*. Maternal metformin treatment prevented some of these changes in *LEP*, *ADIPOR2* and partially in *AR* in girls, and in *LEP* and *AMH* in boys. Maternal BMI at early pregnancy was inversely correlated with the methylation levels of the ChrX-67544981 site in the whole group of girls ($r = -0.530$, $p = 0.008$) and with the global Z-score in all boys ($r = -0.539$, $p = 0.007$). These data indicate that the intrauterine PCOS environment predisposes the offspring to acquire certain sex-dependent DNA methylation patterns in the promoter regions of metabolic and reproductive genes.

ARTICLE HISTORY

Received 13 November 2019
Revised 18 March 2020
Accepted 26 March 2020

KEYWORDS



Epigenetic; polycystic ovary syndrome (PCOS); androgen receptor; leptin; offspring


Introduction

Polycystic ovary syndrome (PCOS) is a highly prevalent and heterogeneous disorder in women of reproductive age, characterized by hyperandrogenism and chronic anovulation, and closely associated with insulin resistance and obesity [1]. We and other authors have demonstrated that androgen excess and metabolic disturbances persist in PCOS women during pregnancy, predisposing to complications such as gestational diabetes (GDM) and pregnancy-induced hypertension. Moreover, this adverse maternal environment has also been associated with deleterious consequences for the foetus such as alterations in birth weight and development of metabolic and cardiovascular

diseases during adult life [2,3]. Some of these disturbances are sex specific indicating that the maternal environment affects the male and female foetuses differently.

In previous studies we have observed higher leptin concentrations in cord blood of PCOS newborns compared to controls [4], a marker that has been associated with disturbances in BMI and insulin levels in PCOS women [5]. Daughters of PCOS women have higher antimüllerian hormone (AMH) concentrations since early infancy to puberty, evidencing an increased follicular mass [6,7] and an increased ovarian volume and hyperandrogenism during early and late puberty, respectively [8]. Regarding metabolic alterations, hypoadiponectinemia is present before the onset of

CONTACT Manuel Maliqueo  mmaliqueo@uchile.cl  Lab. Of Endocrinology, Dept. Of Medicine W. Division, School of Medicine, Carlos Schachtebeck (Ex Las Palmeras) 299, Interior Quinta Normal, Casilla 33052, Correo 33, Santiago 8320000, Chile

 Supplemental data for this article can be accessed [here](#).

© 2020 Informa UK Limited, trading as Taylor & Francis Group

puberty and hyperinsulinemia, reflecting insulin resistance, since prepuberty and later on [8,9]. On the other hand, sons of PCOS mothers show higher AMH concentrations from early infancy to prepuberty, suggesting an increase in the Sertoli cell number or function [10]. Moreover, these boys usually exhibit higher body weight since early infancy and insulin resistance when they get older [11]. Therefore, it seems that altered levels of leptin, adiponectin and AMH along with an abnormal androgen action are common features that appear since early infancy in both daughters and sons born to PCOS mothers. It is known that the androgen receptor modulates androgen action and several studies have supported that a higher activity in the AR is a determining factor in PCOS development [12–14].

During the last years, metformin has been used to treat the maternal complications associated with GDM and PCOS. Moreover, we have previously demonstrated that metformin can improve the altered endocrine-metabolic environment of PCOS mothers reducing AMH levels in their daughters, which might be associated with a decrease in their follicular mass [15]. Nevertheless, its long-term effects in the offspring could be debatable and need more research to be established.

It is now known that multiple mechanisms contribute to foetal programming in PCOS including genetic, epigenetic and environmental factors [16–19]. Epigenetics is a molecular phenomenon that regulates gene expression without changes in the DNA sequence modulating tissue-specific gene expression, genomic imprinting and X-chromosome inactivation [20]. Epigenetic modifications consist mainly of DNA methylation, histone modifications, chromatin reconstruction, and expression of non-coding RNA [21]. DNA methylation is the most stable and best understood epigenetic mechanism [22,23], which consists in the addition of methyl (-CH₃) groups to the 5-carbon of cytosine mainly in CpG-dinucleotides (CpGs) regulating transcriptional expression of specific genes [24]. It has also been proposed that exposure to androgen excess during prenatal life may induce epigenetic changes inducing long-term modifications in the offspring [25]. Moreover, in PCOS women, specific genes have been demonstrated to be associated with aberrant DNA methylation in tissues and pathways associated to PCOS

dysfunction [26–31]. In this context, it has been proposed that differences in the androgen receptor DNA methylation pattern could be associated to hyperandrogenism [32]. Recent studies suggest that adipokines are involved in the foetal metabolic health programming through epigenetic adaptations [33]. Finally, recent results showed a decreased methylation level of the AMH gene associated with an increase in AMH follicular levels in PCOS women [34]. Then, alterations observed in children born to PCOS women could be attributed to these modifications. Until now, only one study has approached this issue showing a differential DNA methylation pattern in umbilical cord blood from children born to PCOS women [35].

In the present study we hypothesized that, depending on their sex, children born to PCOS women could have a particular methylation pattern in the promoter region of key reproductive and metabolic genes, which may be modulated by the intrauterine environment. Therefore, our aim was to evaluate, in genomic DNA from whole blood, the methylation pattern of promoter regions of reproductive and metabolic genes in the offspring of PCOS women during early infancy (2–3 months of age) and compare it with controls and with children from PCOS women treated with metformin during pregnancy. Based on previous observations, we focused our analysis on the promoter regions of leptin (*LEP*), leptin receptor (*LEPR*), adiponectin (*ADIPOQ*), adiponectin receptor 1 and 2 (*ADIPOR1*, *ADIPOR2*), antimüllerian hormone (*AMH*), and the androgen receptor (*AR*) genes.

Subjects and methods

Subjects

Twenty-four Chilean infants born to PCOS women (PCOS) and 24 born to non-PCOS women (control) were included in the study. The PCOS daughters and sons groups included 12 female and 12 male infants (2–3 months old), born to PCOS mothers. The control daughters and sons groups included 12 female and 12 male infants born to mothers with regular menses and without hyperandrogenism. None of the subjects included in the study were genetically related with

each other. In the PCOS group, 12 women were treated with metformin during the whole period of pregnancy (PCOS+M). PCOS and control infants were born from spontaneous singleton pregnancies. All infants were studied during early infancy (2–3 months of age). Most of these infants were included in previous studies carried out by our group [10,11,15]. Inclusion criteria for PCOS mothers and control mothers were similar to those previously reported [8,15].

The protocol was approved by the Institutional Review Board of the Faculty of Medicine University of Chile (Approval of Research Project N°032-2015). All parents signed an informed consent before entering the study.

Pregnant women study protocol

PCOS mothers were recruited from patients attending the Unit of Endocrinology and Reproductive Medicine at the University of Chile who had desired fertility. Diagnosis of PCOS was made according to the diagnostic criteria for PCOS of the National Institutes of Health (NIH) consensus [36]. As part of their initial evaluation, all the patients underwent a lifestyle assessment and were placed on a diet and exercise treatment programme as previously described [15]. In addition, most of them received 1,500–2,000 mg metformin in standard formulation based on their weight, medication tolerance, and insulin levels. PCOS patients were instructed to stop metformin treatment upon a positive pregnancy test and those that required it continued with the medication during the whole pregnancy.

No medications to induce ovulation, such as clomiphene citrate or exogenous gonadotropins, were used. We excluded patients with hyperprolactinaemia, androgen-secreting neoplasm, Cushing syndrome, late-onset 21-hydroxylase deficiency, or thyroid disease.

As a control group, we selected pregnant women of similar age and socioeconomic level as the PCOS patients. These pregnant women had a history of regular 28- to 32-day menstrual cycles, absence of hirsutism and other clinical manifestations of hyperandrogenism, infertility, pregnancy complications, galactorrhoea, and thyroid dysfunction. All were healthy and were not receiving any

drug therapy. These women were recruited from the antenatal care unit of San Juan de Dios hospital (Santiago, Chile) from the 12th week of gestation.

In all pregnant women, duration of gestation, initial and final body mass index (BMI), and weight gain during pregnancy were recorded. During gestational weeks 22–28, all women were classified as having gestational diabetes mellitus or pregnancy-induced hypertension in accordance with the World Health Organization criteria (fasting glucose values >105 mg/dL; 2-hour glucose postload >140 mg/dL), pregnancy-induced hypertension (blood pressure \geq 140/90 mm Hg without proteinuria at a gestational age > 20 weeks on two or more occasions) or preeclampsia (blood pressure \geq 140/90 mm Hg with proteinuria > 0.3 g/24 h after 20 weeks' gestation).

Offspring study protocol

All infants were examined twice, once during the first 3 days of life and again at 2–3 months of age. On both occasions the physical examination included weight and length, following the scheme described in previous studies in which most of these children participated [7,10,11,15]. Gestational age and the type of feeding was registered (exclusive breastfeeding, formula or mixed). In all infants, a blood sample was taken and stored at -80°C for DNA analysis.

Methylation analysis

DNA isolation. Genomic DNA was extracted from peripheral blood leukocytes in all infants using the E.Z.N.A.® Blood DNA Midi Kit (Omega Bio-tek, Inc. Qiagen, Hilden, Germany) following instructions provided by the manufacturer. The concentration and purity of DNA was determined using a Nanodrop spectrophotometer (Tecan Infinite 200 PRO).

Assay design, sample preparation, and multiplex targeted amplification. We selected the promoter regions of seven genes that, according to our previous observations and the literature, could be involved in the metabolic and endocrine changes found in the offspring of PCOS women, including leptin (*LEP*), leptin receptor (*LEPR*), adiponectin

(*ADIPOQ*), adiponectin receptor 1 (*ADIPOR1*), adiponectin receptor 2 (*ADIPOR2*), anti-Müllerian hormone (*AMH*), and androgen receptor (*AR*) (Supplementary Table 1). Genomic DNA was bisulphite modified and then sequenced by the Zymo Research Corporation (Irvine, CA, USA). Assays were designed targeting CpG sites in the specified regions of interest (ROI) using primers created with Rosefinch, Zymo Research's proprietary sodium bisulphite converted DNA-specific primer design tool (Supplementary Table 2). DNA samples were bisulphite converted using the EZ DNA Methylation-Lightning™ Kit (D5030, Zymo Research) according to the manufacturer's instructions. The following processes included a targeted sequencing for DNA methylation analysis at multiple loci using a multiplex PCR strategy in combination with Next-Generation Sequencing (NGS) (MiSeq, Illumina, Inc., San Diego, CA). Multiplex amplification of all samples using ROI specific primer pairs and the Fluidigm Access Array™ System was performed according to the manufacturer's instructions. The resulting amplicons were pooled for harvesting and subsequent barcoding according to the Fluidigm instrument's guidelines. After barcoding, samples were purified using ZR-96 DNA Clean & Concentrator™ (D4023, Zymo Research), and then prepared for massively parallel sequencing using a MiSeq V2 300bp Reagent Kit and paired-end sequencing protocol according to the manufacturer's guidelines.

Targeted sequence alignments and data analysis.

Sequence reads were identified using standard Illumina base-calling software and then analysed using a Zymo Research proprietary analysis pipeline, which is written in Python. Low quality nucleotides and adapter sequences were trimmed off during analysis QC. Sequence reads were aligned back to the reference genome using Bismark (<http://www.bioinformatics.babraham.ac.uk/projects/bismark/>), an aligner optimized for bisulphite sequence data and methylation calling [37]. Paired-end alignment was used as default thus requiring both read 1 and read 2 to be aligned within a certain distance; otherwise both read 1 and read 2 were discarded. Index files were constructed using the `bismark_genome_preparation`

command and the entire reference genome (GRCh38/hg38). The non-directional parameter was applied while running Bismark. All other parameters were set to default. Nucleotides in primers were trimmed off from amplicons during methylation calling.

Data analysis. The methylation level (β -value) of each sampled cytosine was estimated as the number of reads reporting a C, divided by the total number of reads reporting a C or T. Differential methylation was assessed per CpG site including samples with at least 10 reads. Moreover, Z-score value to every CpG site of each gene promoter region was calculated according the method proposed by Hertzberg [38]. For the calculation of the z-score of each promoter region, the sum of each individual z-score value was considered. Finally, we calculated a global z-score value, with the sum of each site that was statistically different between the PCOS and control group.

Transcription factors analysis. In order to identify potential transcription factor binding sites in a promoter sequence, computational identification was performed using TFSITESCAN tools and database (<http://www.ifti.org/cgi-bin/ifti/Tfsitescan.pl>). Only transcription factors binding on or closely near the CpGs were further studied.

Statistical evaluation

Data are expressed as median and range for anthropometric and biochemical variables, and as mean and standard deviation for DNA methylation. Normal distribution was assessed by the Kolmogorov-Smirnov test. The β -value and z-scores comparisons were performed according to the sex of the infants. Differences between groups were calculated through one-way ANOVA followed by Bonferroni post hoc test when data were normally distributed or Kruskal Wallis followed by Dunn test for skewed data. Categorical data were analysed using χ^2 or Fisher's exact test. Spearman correlations were used to evaluate the relationship between the variables of interest. Statistical analysis was performed using SPSS 23.0 package. A p-value of less than 0.05 was considered to be statistically significant.

Results

Clinical maternal data

Clinical characteristics of pregnant control and PCOS women (treated and non-treated with metformin during pregnancy) are shown in Table 1. PCOS women treated with metformin were older than control women ($P = 0.010$). Moreover, pre-pregnancy body weight, BMI and the prevalence of overweight/obesity were significantly higher in those PCOS women that required metformin during pregnancy compared to control women ($P = 0.002$, $P < 0.001$ and $P = 0.004$, respectively). At the beginning of pregnancy, both PCOS women treated and non-treated with metformin showed higher BMI compared to control women ($P = 0.002$ and $P < 0.002$, respectively). At the third trimester, BMI was higher in PCOS women compared to control women ($P = 0.029$). In turn, gestational weight gain (GWG) was lower in PCOS treated with metformin compared to controls and non-treated PCOS ($P = 0.001$ and $P = 0.035$, respectively). No differences were observed in the prevalence of pregnancy-induced hypertension but gestational diabetes mellitus (GDM) was more prevalent in both groups of PCOS women compared to controls. The clinical characteristics of

PCOS women at diagnosis are shown in supplementary table 3.

Infant clinical data

Clinical and anthropometric characteristics of infants born to control and PCOS women are shown in Table 2. At birth, daughters born to PCOS+M showed lower gestational age than controls ($P = 0.004$), whereas birth length tended to be lower in this group of girls compared to controls ($P = 0.074$). On the other hand, in sons, there were no differences between groups regarding clinical and anthropometric variables. The prevalence of small (SGA) and large (LGA) for gestational age was similar between groups in both daughters and sons.

At the time of study, there were no differences in age between groups both in daughters and sons. Z-score of weight and length were lower in daughters of PCOS women treated with metformin during pregnancy compared to girls born to control women ($P = 0.034$ and $P = 0.010$). In turn, sons of PCOS+M tended to be heavier and gained more weight from birth to study time ($P = 0.060$ and $P = 0.037$, respectively). By the time of the study, the prevalence of exclusive maternal breastfeeding was similar between groups both in daughters and sons.

Table 1. Clinical and biochemical characteristics of control and PCOS pregnant women with (PCOS+M) and without metformin (PCOS).

	Control (n = 24)	PCOS (n = 12)	PCOS+M (n = 12)	P-values
Pre-pregnancy				
Age (years)	23.5 (20.2–30.7)	29.5 (26.0–31.0)	30.5 (30.0–35.2) ^b	0.013
Weight (kg)	59.5 (52.8–66.0)	69.0 (56.0–80.0)	72.0 (68.0–76.8) ^b	0.002
BMI (Kg/m ²)	22.9 (21.1–26.0)	26.1 (23.7–29.1)	29.3 (27.1–30.9) ^b	<0.001
Overweight/obesity (%)	29.2	58.3	83.3 ^b	0.007
At beginning				
Weight (kg)	59.0 (52.5–66.0)	69.0 (57.0–80.0)	70.8 (68.0–77.0) ^b	0.002
BMI (Kg/m ²)	23.7 (21.1–25.7)	27.6 (24.4–29.9) ^a	28.8 (27.1–30.9) ^b	<0.001
At third trimester				
Weight (Kg)	71.0 (65.8–77.8)	78.0 (69.0–90.0) ^a	78.8 (70.9–81.5)	0.096
BMI	29.1 (26.7 – 31.3)	30.2 (28.5 – 36.1) ^a	31.9 (28.2 – 32.4)	0.026
SBP (mm Hg)	120 (110–120)	110 (105–110)	120 (110–120)	0.087
DBP (mm Hg)	70 (60–77)	62 (60–70)	70 (70 – 70)	0.448
GWG (Kg)	12.9 (8.2–16.5)	11.0 (6.5–15.8)	5.0 (2.8–7.9) ^{b, c}	0.001
PIH (%) (n)	0	8.3 (1/12)	0 (0/12)	0.216
GDM (%) (n)	0	16.7 (2/12) ^a	66.7 (8/12) ^{b, c}	<0.001

BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; GWG: gestational weight gain; PIH: pregnancy induced-hypertension; GDM: gestational diabetes mellitus. Data are expressed as median and interquartile range for continuous variables and percentage for categorical variables. For continuous variables differences were calculated by one way ANOVA test followed by Bonferroni test or Kruskal Wallis followed by Dunn tests according to the normal distribution of data. Categorical variables were analysed by chi-square test. ^a $P < 0.05$ between control and PCOS; ^b $P < 0.05$ between control and PCOS+M; ^c $P < 0.05$ between PCOS and PCOS+M.

Table 2. Clinical characteristics of control and PCOS infants (daughters and sons) born to control and PCOS mothers treated (PCOS+M) and non-treated (PCOS) with metformin during pregnancy.

	Daughters				Sons				P-values
	Control (n = 12)	PCOS (n = 6)	PCOS+M (n = 6)	P-values	Control (n = 12)	PCOS (n = 6)	PCOS+M (n = 6)	P-values	
At birth									
Gestational age (wk)	39.0 (39.0–40.0)	39.0 (38.0–40.0)	38.0 (36.0–38.0) ^b	0.005	39.5 (38.2–40.0)	39.5 (38.7–41.0)	39.0 (37.7–39.5)	0.474	
Weight (g)	3545 (3257–3750)	3275 (2690–3905)	3285 (2895–3515)	0.346	3575 (3402–4010)	3588 (2965–3875)	3417 (3015–3692)	0.534	
Z-score weight	0.76 (0.15–1.06)	0.04 (–1.26–1.87)	0.34 (–0.25–0.93)	0.601	1.11 (0.55–1.93)	1.03 (–0.73–1.58)	0.57 (–0.25–1.34)	0.631	
Length (cm)	50.0 (49.0–51.0)	47.2 (44.7–50.4)	47.7 (45.9–49.2)	0.046	50.0 (49.2–51.7)	50.0 (49.2–51.0)	49.5 (48.2–51.4)	0.659	
Z-score length	0.22 (–0.27–0.68)	–0.39 (–1.38–0.60)	–0.12 (–0.83–0.17)	0.381	0.22 (0.06–0.85)	0.30 (–0.25–0.54)	0.13 (–0.70–0.88)	0.775	
SGA (%) (n)	0 (0/12)	16.7 (1/6)	0 (0/6)	0.209	8.3 (1/12)	16.7 (1/6)	0 (0/6)	0.579	
LGA (%) (n)	16.7 (2/12)	33.3 (2/6)	0 (0/6)	0.301	33.3 (4/12)	33.3 (2/6)	16.7 (1/6)	0.739	
At study									
Age (years)	0.17 (0.17–0.23)	0.25 (0.17–0.25)	0.25 (0.23–0.25) ^b	0.006	0.17 (0.17–0.25)	0.21 (0.17–0.27)	0.25 (0.17–0.33)	0.077	
Weight (g)	6115 (5327–6650)	6335 (5425–6605)	5175 (4747–6337)	0.336	5600 (5400–8160)	6400 (6050–7540)	6375 (5587–7012)	0.040	
Z-score weight	0.94 (0.18–1.48)	0.73 (–0.04–1.28)	–1.02 (–1.52–0.42) ^b	0.032	–0.29 (–0.95–0.48)	0.49 (–0.04–1.79)	0.68 (–0.79–2.06)	0.080	
Length (cm)	58.0 (57.0–60.7)	57.5 (55.5–59.0)	57.5 (55.2–60.1)	0.419	59.0 (58.0–60.9)	60.0 (59.0–62.5)	57.5 (57.0–61.0)	0.267	
Z-score length	–0.13 (–0.59–1.45)	–0.73 (–1.56 – –0.08)	–1.30 (–2.17 – –0.20) ^b	0.008	–0.24 (–0.71–0.62)	0.03 (–0.57–1.43)	–0.33 (–1.71–1.36)	0.789	
Weight gain (g)	2735 (1820–3212)	2620 (2390–3170)	2485 (1480–3327)	0.886	2145 (1652–2732)	2967 (2270–4147)	3615 (2881–4510) ^b	0.020	
EMB (%) (n)	80 (8/10)	83.3 (5/6)	50.0 (3/6)	0.338	77.8 (7/9)	25.0 (1/4)	66.7 (4/6)	0.186	

Results are expressed as median and interquartile range. SGA: small for gestational age; LGA: large for gestational age and EMB: exclusive maternal breastfeeding. Data are expressed as median and interquartile range for continuous variables and percentage for categorical variables. For continuous variables differences were calculated by one way ANOVA test followed by Bonferroni test or Kruskal Wallis followed by Dunn tests according to the normal distribution of data. Categorical variables were analysed by chi-square test. ^aP < 0.05 between control and PCOS; ^bP < 0.05 between control and PCOS+M; ^cP < 0.05 between PCOS and PCOS+M.

Methylation analysis in promoter region of candidate genes

In total, the methylation levels in 368 CpG sites distributed among the promoter regions of 7 genes (*LEP*, *ADIPOQ*, *AMH*, *LEPR*, *ADIPOR1*, *ADIPOR2* and *AR*) were analysed.

Daughters showed differences in 1 CpG site located in the promoter region of *LEPR*, 2 in *LEP*, 1 in *ADIPOR2* and 2 in *AR* (Figure 1(a–d)). In the Chr1-65419664 site of the *LEPR* promoter, the proportion of methylation was higher in infants born to PCOS and PCOS+M compared to those born to control women ($P = 0.016$ and $P = 0.037$, respectively) (Figure 1(a)). Moreover, the Chr7-128240906 and Chr7-128241078 sites in the promoter of *LEP* exhibited higher methylation levels in PCOS+M infants compared to PCOS ($P = 0.007$ and $P = 0.033$, respectively). A trend to higher methylation in the Chr7-128240906 site was observed in control infants compared to PCOS ($P = 0.072$) (Figure 1(b)). In the Chr12-1690290 site of the *ADIPOR2* promoter, increased methylation levels were observed in infants born to PCOS mothers compared to controls and PCOS+M. ($P = 0.022$ and $P = 0.019$, respectively) (Figure 1(c)). Moreover, the ChrX-67543969 and ChrX-67544981 sites of the *AR* promoter were less methylated in PCOS compared to controls ($P = 0.005$ and $P = 0.049$, respectively) (Figure 1(d)).

In sons, 5 CpG sites in the promoter region of *LEP*, 3 in *AMH*, and 9 in *AR* showed differences in methylation levels between groups (Figure 2(a–c)). In the promoter region of *LEP* (Figure 2(a)), the Chr7-128240873 site had lower methylation levels in PCOS compared to controls ($P = 0.037$), whereas in Chr7-128241155 methylation was lower in PCOS than in PCOS+M ($P = 0.034$). On the other hand, methylation in Chr7-128241074 was higher in PCOS compared to controls and PCOS+M ($P = 0.008$ and $P = 0.012$, respectively). In turn, methylation levels at the Chr7-128241028 site were lower ($P = 0.028$), whereas in Chr7-128241387 were higher in PCOS+M compared to controls ($P = 0.028$). In the promoter region of *AMH* (Figure 2(b)), methylation levels in Chr19-2248956 and Chr19-2249331 were lower in PCOS than in controls ($P = 0.030$ and $P = 0.010$, respectively) and the last site was also lower in PCOS compared to PCOS+M ($P = 0.010$).

At Chr19-2249336, sons born to PCOS+M mothers had higher methylation levels than controls ($P = 0.046$). Finally, the *AR* promoter showed higher methylation levels in PCOS+M sons compared to controls and PCOS at the ChrX-67543762 site ($P < 0.0001$ and $P < 0.0001$, respectively) and lower methylation levels at ChrX-67544032 compared to controls and PCOS ($P < 0.0001$ and $P = 0.048$, respectively). In the other CpG sites, lower methylation levels were observed in sons born to PCOS+M compared to controls (ChrX-67543849 ($P = 0.006$), ChrX-67543889 ($P = 0.043$), ChrX-67543895 ($P = 0.015$), ChrX-67543899 ($P = 0.017$), ChrX-67544040 ($P = 0.006$), ChrX-67544221 ($P = 0.041$) and ChrX-67545002 ($P = 0.022$)) (Figure 2(c)).

Methylation Z-score

The Z-scores for the promoter regions of *LEP*, *LEPR*, *ADIPOQ*, *ADIPOR1*, *ADIPOR2*, *AMH* and *AR* were comparable between the groups in both daughters and sons. The same was observed for the global Z-score in daughters (Figure 3(a)). However, the global Z-score was higher in control sons compared to PCOS and PCOS+M ($P = 0.019$ and $P = 0.019$, respectively) (Figure 3(b)).

Correlation analysis

In daughters, the methylation levels of the chrX-67544981 site (*AR*) were significantly and inversely correlated with maternal BMI at early pregnancy (Figure 4(a)). On the other hand, in sons, the methylation levels in chr7-128241028 (*LEP*) and chrX-67543762 (*AR*) were significantly and positively correlated with the Z-Score of length and with the postnatal weight gain between birth and time of study, respectively (Figure 4(b–c)). Moreover, in sons, the global Z-Score of methylation was negatively associated with maternal BMI at early pregnancy and with postnatal weight gain (Figure 4(d–e)).

Predicted transcription factor (TF) binding sites

In daughters, the differently methylated site, Chr7-128240906, in the *LEP* promoter has putative binding sites for the transcription factors SP1









a. *LEPR* promoterb. *LEP* promoterc. *ADIPOR2* promoterd. *AR* promoter

Figure 1. Methylation levels (β -value) in the promoter regions of the leptin receptor (*LEPR*) (a), leptin (*LEP*) (b), adiponectin receptor 2 (*ADIPOR2*) (c) and androgen receptor (*AR*) genes (d) in daughters of control (control, $n = 12$), PCOS women (PCOS, $n = 6$) and PCOS women treated with metformin during pregnancy (PCOS+M, $n = 6$). Data are shown as median \pm SEM. Dots indicate the cases in each group. Differences were calculated by one-way ANOVA followed by Bonferroni test or Kruskal-Wallis test followed by Dunn test. ^a $P < 0.05$ between control and PCOS; ^b $P < 0.05$ between control and PCOS+M; ^c $P < 0.05$ between PCOS and PCOS+M.

(specificity protein 1) and GKLF (gut-enriched Kruppel-like factor). Moreover, the Chr1-65419662 site of the *LEPR* promoter binds SOX9 (SRY-Box 9 Protein), and the Chr12-1690290 site

of the *ADIPOR2* promoter binds E4 F1 (E4F transcription factor 1). In turn, the *AR* promoter has different methylation sites associated with EGR1 (early growth response 1), SET (Suppressor of




a. *LEP* promoterb. *AMH* promoterc. *AR* promoter

Figure 2. Methylation levels (β -value) in the promoter regions of the leptin (*LEP*) (a), antimüllerian hormone (*AMH*) (b) and androgen receptor (*AR*) genes (c) in sons of control (control, $n = 12$), PCOS women (PCOS, $n = 6$) and PCOS women treated with metformin during pregnancy (PCOS+M, $n = 6$). Data are shown as median \pm SEM. Dots indicate the cases in each group. Differences were calculated by one-way ANOVA followed by Bonferroni test or Kruskal-Wallis test followed by Dunn test. ^a $P < 0.05$ between control and PCOS; ^b $P < 0.05$ between control and PCOS+M; ^c $P < 0.05$ between PCOS and PCOS+M.

variegation, Enhancer of Zeste, Trithorax) and MYND (myeloid:Nervy:DEAF1) in the ChrX-67543969 site, whereas the ChrX-67544580 site binds MED1 (mediator of RNA polymerase II transcription subunit 1).

In sons, CpG sites in the *LEP* promoter exhibit binding sites for AP2 (Activator protein 2) in Chr7-128241387 and GCF (GC factor) in Chr7-128241155. The Chr19-2249336 site of the *AMH* promoter can be regulated by CNRE (cAMP




Figure 3. Z-Score of the promoter regions of *LEP*, *LEPR*, *ADIPOQ*, *ADIPOR1*, *ADIPOR2*, *AMH* and *AR* in daughters and sons of control (control, $n = 12/12$), PCOS women (PCOS, $n = 6/6$) and PCOS women treated with metformin during pregnancy (PCOS+M, $n = 6/6$). Data are shown as median \pm SEM. Dots indicate the cases in each group. Differences were calculated by Kruskal-Wallis test followed by Dunn test. ^a $P < 0.05$ between control and PCOS; ^b $P < 0.05$ between control and PCOS+M.

negative response element). In the *AR* promoter, we found 4 sites that bind transcription factors: the ChrX-67543762 and ChrX-67543895 sites bind E2 F factor, the ChrX-67543849 site binds XRE (xenobiotic responsive element), and EBS1 (Ets binding site 1) and EGR1 are very close to this site. Finally, AP2 alpha and gamma, and CAF1 (chromatin assembly factor complex) are transcription factors associated to the ChrX-67545002 site.

Discussion

Using a targeted NGS approach, we found that the offspring of women with PCOS, at early infancy, show a sex-specific DNA methylation pattern in the promoter regions of genes associated with reproductive and metabolic features of PCOS. Interestingly, metformin treatment during pregnancy in PCOS women normalized the methylation levels in some of these CpG sites, suggesting that the intrauterine environment of PCOS women may confer a different methylation pattern to their offspring compared to children born to women without PCOS.

Both sons and daughters of women with PCOS showed differences in the methylation levels of specific sites in the promoter regions of *LEP* and *AR*. We also observed that daughters of these women had changes in the methylation levels of *LEPR* and *ADIPOR2*. Previous data indicate that deregulation of the expression and secretion of leptin in metabolic diseases is associated with modifications in its promoter methylation [39].

Interestingly, it has been described that DNA methylation of the *LEP* and *ADIPOR2* promoters in cord blood and placenta are associated with maternal and infant perinatal factors [40,41]. In this regard, in placenta of women with PCOS, a reduced gene expression of *LEP* and *LEPR* have been observed, whereas in cord blood, higher circulating levels of leptin have been reported in newborns of women with PCOS [4,42]. Similarly, prenatal androgenization in the sheep model, resembling PCOS pregnancy, produces an increase of the *ADIPOR2* gene expression in fat, muscle and liver of the female offspring at the peripubertal period [43]. It has been observed that the expression of adipokines and their receptors is modulated by the promoter methylation status [44–47], moreover, methylation of these genes has been associated with metabolic alterations and BMI [47,48]. In the same line, we have described that the circulating leptin-adiponectin ratio is associated with metabolic abnormalities in daughters of women with PCOS during the pubertal transition [49]. Therefore, it is possible to suggest that alterations in the leptin-adiponectin system that have been frequently observed at different ages in the offspring of women with PCOS, could be determined by epigenetic modifications that occur during early life.

Same as with the *LEP* promoter, *AR* exhibited a differential pattern of methylation according to sex, indicating that epigenetic modifications could affect the expression of the androgen receptor, and hence, androgen action. As stated before,




Figure 4. Correlation analysis between the methylation levels (β -value) of the CpG sites of the promoter regions of the *AR* (chromosome X, ChrX), and *LEP* (chromosome 7, Chr7) genes (and Z-Score of the analysed promoter regions), and the maternal characteristics and anthropometric parameters at birth and postnatal age in daughters and sons. Dots indicate the cases in each group. The associations between variables were calculated by Spearman's rank correlation analysis. $P < 0.05$ was considered as significant level.

hyperandrogenism is central in the pathophysiology of PCOS. Therefore, our observations in peripheral leukocytes from PCOS daughters agree with this asseveration because a hypomethylation in the *AR* promoter suggests an increased expression of the *AR*. On the other hand, DNA methylation is also an important epigenetic mechanism involved in the X chromosome inactivation (XCI), where the *AR* gene is [50]. It has been proposed that a non-random XCI, may contribute significantly to the expression of PCOS [14]. Nevertheless, while this analysis was not considered in the present study, in a previous report we did not find significant differences in the pattern of XCI between daughters of PCOS and control women at 2–3 months of life [51], as has been reported in adult PCOS women [32,52,53]. In addition, in that study we showed that shorter CAG repeats in the *AR*, which favours its activity, are associated with abnormalities in the

lipid profile of young daughters of PCOS women [51]. Consistently, an elevated protein and gene expression of the androgen receptor have been found in the ovaries and liver of the female offspring of prenatally androgenized sheep, indicating that the mechanisms that regulate the sensitivity to androgen action are determined during foetal life [54,55]. Moreover, the *AR* promoter methylation has been linked with BMI and fat mass according to gender [56–58].

One of the most constant features that we have observed in the offspring of PCOS women is high AMH serum concentrations. In the present study only sons of PCOS women showed lower methylation levels in CpG sites of the *AMH* promoter, which is in accordance with the higher serum AMH concentrations described in them during infancy and childhood [59]. On the other hand, we did not observe differences in *AMH* DNA

methylation in girls, which could suggest that the increase in the follicular mass is responsible for this feature more than an increased gene expression. Thus, it seems that, opposite to what was observed in boys, apparently this gene is not modified by epigenetic regulation in girls.

It is currently accepted that an adverse *in utero* environment can influence the establishment of epigenetic marks during foetal development with consequences later in life [60,61]. In this regard, the negative correlation found between maternal BMI and the CpG methylation level in the *AR* promoter in girls and with the global z-score in boys, highlights the importance of the maternal metabolic condition for the acquisition of specific epigenetic marks in their offspring. On the other hand, the relationships found between the methylation levels of the *LEP* and *AR* sites and the global methylation z-score with postnatal anthropometric features in male newborns highlights the effect of these epigenetic mechanisms in postnatal life. Regarding these anthropometric parameters, only postnatal weight gain was different among sons, specifically sons of PCOS women who took metformin during pregnancy gained almost 1.5 kg more than sons born to control women, while the z-score for length at birth was comparable between groups.

Previously, we reported that metformin treatment ameliorates the endocrine and metabolic alterations in women with PCOS during pregnancy resulting in the improvement of ovarian PCOS markers in their female offspring [15]. Along with this, a recent study demonstrated that short-term metformin administration, at therapeutic doses, has a rapid effect on epigenetic regulation in human white blood cells producing both hypo and hypermethylation in the promoters of different genes [62]. In the present study, we observed that metformin treatment during pregnancy reversed the effect of PCOS on the methylation patterns of some CpG sites of the *LEP*, *ADIPOR2* and had a partial effect on the *AR* promoters in daughters, whereas in sons, it had an effect on the *LEP* and *AMH* promoters. Interestingly, in sons of women with PCOS, in the CpG sites of the *AR* gene, the methylation level was only modified in the metformin group, especially in ChrX-67543762 and ChrX-67544032,

which seems to suggest that the PCOS effect was enhanced by metformin treatment. The impact of these findings is unclear as the long-term impact of intrauterine metformin exposure on childhood development is an unanswered question. Studies evaluating children of patients with gestational diabetes exposed to metformin vs. insulin show a neutral effect in body fat, visceral adipose tissue and intrahepatic fat [63]. We observed that sons of women with PCOS treated with metformin gained more weight from birth until 3 months old, which is consistent with previous observations that have shown an increase in BMI and in the prevalence of overweight or obesity in prepubertal PCOS sons exposed to metformin during pregnancy, (4–7 years old) [64,65]. Nevertheless, it is important to note that in those PCOS women who were medicated with metformin during pregnancy, a large percentage developed GDM probably due to their higher pre-pregnancy metabolic risk, which makes difficult to dissect the effect of metformin from the effect of maternal GDM. In this regard, several studies have established an association between GDM and an altered epigenetic profile in the offspring, finding both increases and decreases of methylation levels depending on the genes studied [66,67]. The significance of these findings in terms of long-term cardiovascular risk is uncertain.

DNA methylation is involved in essential processes that regulate gene expression such as the binding of transcription factors to regulatory elements or direct transcriptional inhibition as in the X chromosome inactivation [68]. DNA methylation has been generally related to gene inactivation and to repression of transcription factor binding ability [69–74]. Therefore, the final effect depends on both mechanisms [24]. The consequences of the inactivation of a gene are relative, since it depends on whether the expression of such a gene is favourable or deleterious for a particular condition. Unfortunately, we were unable to perform gene expression analysis (RNA from blood leucocytes) since the original study was not designed for this purpose. The *LEP* promoter can potentially bind the transcription factors SP1 and GSK3 (KLF4), which are important regulators of the leptin gene, adipogenesis and oxidative stress [75–78]. Particularly KLF4 also

promotes macrophage polarization towards an antiinflammatory phenotype (M2) [79]. A study with PCOS women showed activation of KLF-4 after treatment with electroacupuncture, associated with epigenetic and transcriptional changes that elicit metabolic improvement [76]. On the other hand, SP1 may also function as a cellular glucose sensor and the effect of its regulation depends on the maturation of the adipocyte [75,78]. Many of these functions have to do with increased leptin transcription. In this context, if the leptin promoter is more methylated, this may indeed inhibit transcription factors binding, avoiding that they exert their action at the promoter level [77,78] and possibly reducing their positive metabolic effects. On the other hand, the transcription factors EGR, MED1, E2 F and XRE have been related to AR promoter regulation. In this regard, the overexpression of EGR-1 enhances AR translocation to the nucleus increasing its activity [80] and therefore, could contribute to the hyperandrogenic state; interestingly higher levels of this protein have been observed in obese women with PCOS [81]. In turn, MED1 and E2 F have been described as co-activators of the AR, participating in the regulation of the expression of cell cycle genes [82,83], which could be involved in the proliferation of ovarian granulosa cells, a phenomenon that has been observed in females born to prenatally androgenized sheep and in the offspring of women with PCOS [84,85]. Moreover, in humans, polymorphisms of the XRE gene have been associated with susceptibility to polycystic ovaries [86]. It is likely that lower DNA methylation of the AR promoter may favour DNA binding of EGR, MED1, E2 F and XRE increasing AR transcription, which could worsen hyperandrogenism and its consequences in the PCOS condition. Although, we cannot exclude that the binding of some of these transcription factors, such as EGR1, to their target sequences may occur independently of the methylation status [87].

The differential methylation pattern observed in the offspring of PCOS women may reflect adaptive changes generated during pregnancy as a result of an altered intrauterine environment, they may be directly inherited from the mother, or result from a combination of both. Further modulation of these processes may occur during postnatal life

through environmental exposure to other factors such as hormones, nutrients, lifestyle, etc. which may reverse or worsen these effects, making them susceptible for therapeutic interventions [88–90].

Although it would be ideal to evaluate the target tissue this is not always possible. Thus, peripheral blood leucocytes DNA is a good surrogate. In this regard, a genome-wide epigenetic study has reported high consistency between peripheral blood and ovarian tissue from PCOS women [29,91]. However, Sang et al did not find consistency between the methylation level of peripheral blood leukocytes and tissue regarding the follistatin promoter in endometrial tissue of PCOS women [92]. In turn, *LEP* and *ADIPOQ*, methylation in peripheral leukocytes is correlated with their expression in subcutaneous and visceral adipose tissue [93]. Therefore, whole blood could serve as a useful surrogate measure of the tissue status in terms of epigenetics in the PCOS scenario [94–96]. Another limitation of our study is the small simple size, mainly due to the age of the children studied, the careful selection of PCOS patients and the time required to follow the pregnancies. Finally, although it was not contemplated in this study, it would have been very interesting to have the mothers' DNA to compare the methylation pattern with that of their children, since these data would have enriched the interpretation of the results.

In summary, we observed that both daughters and sons born to women with PCOS have sex-dependent differences in the methylation levels of CpG sites in the promoter regions of metabolic and reproductive genes such as *LEP*, *LEPR*, *ADIPOR2*, *AMH* and *AR*. The intrauterine environment at least in part, mediates these modifications, as treatment with metformin during pregnancy is able to change them. Therefore, our data support the concept that the maternal environment in women with PCOS may induce epigenetic modifications in the DNA methylation profile both in their sons and daughters, which can program the expression of future reproductive and metabolic derangements.


Disclosure statement

Authors have no conflict of interests

Funding

This work was supported by the Fondo Nacional de Desarrollo Científico y Tecnológico (National Fund for Scientific and Technological Research) FONDECYT Grant [1151531]; [1181798] and VID research travelling support grant of the University of Chile [UCH-1566]. The authors express their gratitude to Mr Patricio Miranda and Miss Madián García for their commitment and dedication to the study.

ORCID

Bárbara Echiburú  <http://orcid.org/0000-0001-6535-3104>
 Fermín Milagro  <http://orcid.org/0000-0002-3228-9916>
 Francisco Pérez-Bravo  <http://orcid.org/0000-0002-5660-5717>
 Ana Arpón  <http://orcid.org/0000-0002-9508-0431>
 Manuel Maliqueo  <http://orcid.org/0000-0003-3872-0217>

References

- [1] Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. *Nat Rev Endocrinol.* 2018;14(5):270–284.
- [2] Sir-Petermann T, Hittschfeld C, Maliqueo M, et al. Birth weight in offspring of mothers with polycystic ovarian syndrome. *Hum Reprod.* 2005;20(8):2122–2126.
- [3] Vanky E, Engen Hanem LG, Abbott DH. Children born to women with polycystic ovary syndrome—short- and long-term impacts on health and development. *Fertil Steril.* 2019;111(6):1065–1075.
- [4] Maliqueo M, Echiburú B, Crisosto N, et al. Metabolic parameters in cord blood of newborns of women with polycystic ovary syndrome. *Fertil Steril.* 2009;92(1):277–282.
- [5] Chakrabarti J. Serum leptin level in women with polycystic ovary syndrome: correlation with adiposity, insulin, and circulating testosterone. *Ann Med Health Sci Res.* 2013;3(2):191–196.
- [6] Crisosto N, Codner E, Maliqueo M, et al. Anti-Müllerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2007;92(7):2739–2743.
- [7] Sir-Petermann T, Codner E, Maliqueo M, et al. Increased anti-Müllerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2006;91(8):3105–3109.
- [8] Sir-Petermann T, Codner E, Perez V, et al. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2009;94(6):1923–1930.
- [9] Sir-Petermann T, Maliqueo M, Codner E, et al. Early metabolic derangements in daughters of women with polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2007;92(12):4637–4642.
- [10] Recabarren SE, Sir-Petermann T, Rios R, et al. Pituitary and testicular function in sons of women with polycystic ovary syndrome from infancy to adulthood. *J Clin Endocrinol Metab.* 2008;93(9):3318–3324.
- [11] Recabarren SE, Smith R, Rios R, et al. Metabolic profile in sons of women with polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2008;93(5):1820–1826.
- [12] Schuring AN, Welp A, Gromoll J, et al. Role of the CAG repeat polymorphism of the androgen receptor gene in polycystic ovary syndrome (PCOS). *Exp Clin Endocrinol Diabetes.* 2012;120(2):73–79.
- [13] Xita N, Georgiou I, Lazaros L, et al. The role of sex hormone-binding globulin and androgen receptor gene variants in the development of polycystic ovary syndrome. *Hum Reprod.* 2008;23(3):693–698.
- [14] Shah NA, Antoine HJ, Pall M, et al. Association of androgen receptor CAG repeat polymorphism and polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2008;93(5):1939–1945.
- [15] Crisosto N, Echiburú B, Maliqueo M, et al. Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular mass of their daughters. *Fertil Steril.* 2012;97(1):218–224.
- [16] Luque-Ramírez M, San Millán JL, Escobar-Morreale HF. Genomic variants in polycystic ovary syndrome. *Clin Chim Acta.* 2006;366(1–2):14–26.
- [17] Escobar-Morreale HF, Luque-Ramírez M, San Millán JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. *Endocr Rev.* 2005;26(2):251–282.
- [18] Hickey TE, Legro RS, Norman RJ. Epigenetic modification of the X chromosome influences susceptibility to polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2006;91(7):2789–2791.
- [19] Gur EB, Karadeniz M, Turan GA. Fetal programming of polycystic ovary syndrome. *World J Diabetes.* 2015;6(7):936–942.
- [20] Christensen BC, Marsit CJ. Epigenomics in environmental health. *Front Genet.* 2011;2:84.
- [21] Guerrero-Bosagna C, Skinner MK. Environmentally induced epigenetic transgenerational inheritance of phenotype and disease. *Mol Cell Endocrinol.* 2012;354(1–2):3–8.
- [22] Meer A, Mikkelsen TS, Gu H, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. *Nature.* 2008;454(7205):766–770.
- [23] Bird A. DNA methylation patterns and epigenetic memory. *Genes Dev.* 2002;16(1):6–21.
- [24] Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. *Nat Rev Genet.* 2012;13(7):484–492.
- [25] Li Z, Huang H. Epigenetic abnormality: a possible mechanism underlying the fetal origin of polycystic ovary syndrome. *Med Hypotheses.* 2008;70(3):638–642.

- [26] Wang P, Zhao H, Li T, et al. Hypomethylation of the LH/choriogonadotropin receptor promoter region is a potential mechanism underlying susceptibility to polycystic ovary syndrome. *Endocrinology*. 2014;155(4):1445–1452.
- [27] Sang Q, Li X, Wang H, et al. Quantitative methylation level of the EPHX1 promoter in peripheral blood DNA is associated with polycystic ovary syndrome. *PLoS One*. 2014;9(2):e88013.
- [28] Yu YY, Sun CX, Liu YK, et al. Promoter methylation of CYP19A1 gene in Chinese polycystic ovary syndrome patients. *Gynecol Obstet Invest*. 2013;76(4):209–213.
- [29] Wang XX, Wei JZ, Jiao J, et al. Genome-wide DNA methylation and gene expression patterns provide insight into polycystic ovary syndrome development. *Oncotarget*. 2014;5(16):6603–6610.
- [30] Qu F, Wang FF, Yin R, et al. A molecular mechanism underlying ovarian dysfunction of polycystic ovary syndrome: hyperandrogenism induces epigenetic alterations in the granulosa cells. *J Mol Med*. 2012;90(8):911–923.
- [31] Pan JX, Tan YJ, Wang FF, et al. Aberrant expression and DNA methylation of lipid metabolism genes in PCOS: a new insight into its pathogenesis. *Clin Epigenetics*. 2018;10(1):6.
- [32] Hickey T, Chandy A, Norman RJ. The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. *J Clin Endocrinol Metab*. 2002;87(1):161–165.
- [33] Houde AA, Hivert MF, Bouchard L. Fetal epigenetic programming of adipokines. *Adipocyte*. 2013;2(1):41–46.
- [34] Wijaya AD, Febri RR, Desmawati, et al. DNA methylation analysis of anti-mullerian hormone gene in ovarian granulosa cells in PCOS patients. *J Phys*. 2018;1073:032077.
- [35] Lambertini L, Saul SR, Copperman AB, et al. Intrauterine reprogramming of the polycystic ovary syndrome: evidence from a pilot study of cord blood global methylation analysis. *Front Endocrinol (Lausanne)*. 2017;8:352.
- [36] Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif AGJ, Haseltine FP, Merriam GR, editors. *Polycystic ovary syndrome*. Oxford, UK: Blackwell; 1992. p. 59–69.
- [37] Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for bisulfite-seq applications. *Bioinformatics*. 2011;27(11):1571–1572.
- [38] Hertzberg L, Izraeli S, Domany E. STOP: searching for transcription factor motifs using gene expression. *Bioinformatics*. 2007;23(14):1737–1743.
- [39] Wroblewski A, Strycharz J, Swiderska E, et al. Molecular insight into the interaction between epigenetics and leptin in metabolic disorders. *Nutrients*. 2019;11(8):1872.
- [40] Lesseur C, Armstrong DA, Paquette AG, et al. Tissue-specific Leptin promoter DNA methylation is associated with maternal and infant perinatal factors. *Mol Cell Endocrinol*. 2013;381(1–2):160–167.
- [41] Nogues P, Dos Santos E, Jammes H, et al. Maternal obesity influences expression and DNA methylation of the adiponectin and leptin systems in human third-trimester placenta. *Clin Epigenetics*. 2019;11(1):20.
- [42] Maliqueo M, Sundstrom Poromaa I, Vanky E, et al. Placental STAT3 signaling is activated in women with polycystic ovary syndrome. *Hum Reprod*. 2015;30(3):692–700.
- [43] Puttabyatappa M, Andriessen V, Mesquitta M, et al. Developmental programming: impact of gestational steroid and metabolic milieus on mediators of insulin sensitivity in prenatal testosterone-treated female sheep. *Endocrinology*. 2017;158(9):2783–2798.
- [44] Tobi EW, Lumey LH, Talens RP, et al. DNA methylation differences after exposure to prenatal famine are common and timing- and sex-specific. *Hum Mol Genet*. 2009;18(21):4046–4053.
- [45] Stoger R. In vivo methylation patterns of the leptin promoter in human and mouse. *Epigenetics*. 2006;1(4):155–162.
- [46] Melzner I, Scott V, Dorsch K, et al. Leptin gene expression in human preadipocytes is switched on by maturation-induced demethylation of distinct CpGs in its proximal promoter. *J Biol Chem*. 2002;277(47):45420–45427.
- [47] Garcia-Cardona MC, Huang F, Garcia-Vivas JM, et al. DNA methylation of leptin and adiponectin promoters in children is reduced by the combined presence of obesity and insulin resistance. *Int J Obes (Lond)*. 2014;38(11):1457–1465.
- [48] Yousefi M, Karmaus W, Zhang H, et al. The methylation of the LEPR/LEPROT genotype at the promoter and body regions influence concentrations of leptin in girls and BMI at age 18 years if their mother smoked during pregnancy. *Int J Mol Epidemiol Genet*. 2013;4(2):86–100.
- [49] Maliqueo M, Galgani JE, Perez-Bravo F, et al. Relationship of serum adipocyte-derived proteins with insulin sensitivity and reproductive features in pre-pubertal and pubertal daughters of polycystic ovary syndrome women. *Eur J Obstet Gynecol Reprod Biol*. 2012;161(1):56–61.
- [50] Heard E, Clerc P, Avner P. X-chromosome inactivation in mammals. *Annu Rev Genet*. 1997;31:571–610.
- [51] Echiburú B, Perez-Bravo F, Maliqueo M, et al. CAG repeat polymorphism of androgen receptor gene and X-chromosome inactivation in daughters of women with polycystic ovary syndrome (PCOS): relationship with endocrine and metabolic parameters. *Gynecol Endocrinol*. 2012;28(7):516–520.
- [52] Rajender S, Carlus SJ, Bansal SK, et al. Androgen receptor CAG repeats length polymorphism and the risk of polycystic ovarian syndrome (PCOS). *PLoS One*. 2013;8(10):e75709.

- [53] Dasgupta S, Sirisha PV, Neelaveni K, et al. Androgen receptor CAG repeat polymorphism and epigenetic influence among the south Indian women with polycystic ovary syndrome. *PLoS One*. 2010;5(8):e12401.
- [54] Ortega HH, Salvetti NR, Padmanabhan V. Developmental programming: prenatal androgen excess disrupts ovarian steroid receptor balance. *Reproduction*. 2009;137(5):865–877.
- [55] Hogg K, Wood C, McNeilly AS, et al. The in utero programming effect of increased maternal androgens and a direct fetal intervention on liver and metabolic function in adult sheep. *PloS One*. 2011;6(9):e24877.
- [56] Ammerpohl O, Bens S, Appari M, et al. Androgen receptor function links human sexual dimorphism to DNA methylation. *PLoS One*. 2013;8(9):e73288.
- [57] Moverare-Skrtic S, Mellstrom D, Vandenput L, et al. Peripheral blood leukocyte distribution and body mass index are associated with the methylation pattern of the androgen receptor promoter. *Endocrine*. 2009;35(2):204–210.
- [58] Vottero A, Capelletti M, Giuliodori S, et al. Decreased androgen receptor gene methylation in premature pubarche: a novel pathogenetic mechanism? *J Clin Endocrinol Metab*. 2006;91(3):968–972.
- [59] Lukas-Croisier C, Lasala C, Nicaud J, et al. Follicle-stimulating hormone increases testicular anti-mullerian hormone (AMH) production through sertoli cell proliferation and a nonclassical cyclic adenosine 5'-monophosphate-mediated activation of the AMH gene. *Mol Endocrinol*. 2003;17(4):550–561.
- [60] Fleisch AF, Wright RO, Baccarelli AA. Environmental epigenetics: a role in endocrine disease? *J Mol Endocrinol*. 2012;49(2):R61–7.
- [61] Gluckman PD, Hanson MA. Developmental and epigenetic pathways to obesity: an evolutionary-developmental perspective. *Int J Obesity*. 2008;32(Suppl 7):S62–71.
- [62] Elbere I, Silamikelis I, Ustinova M, et al. Significantly altered peripheral blood cell DNA methylation profile as a result of immediate effect of metformin use in healthy individuals. *Clin Epigenetics*. 2018;10(1):156.
- [63] Rowan JA, Rush EC, Plank LD, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age. *BMJ Open Diabetes Res Care*. 2018;6(1):e000456.
- [64] Hanem LGE, Stridsklev S, Juliusson PB, et al. Metformin use in PCOS pregnancies increases the risk of offspring overweight at 4 years of age: follow-up of two RCTs. *J Clin Endocrinol Metab*. 2018;103(4):1612–1621.
- [65] Hanem LGE, Salvesen O, Juliusson PB, et al. Intrauterine metformin exposure and offspring cardio-metabolic risk factors (PedMet study): a 5–10 year follow-up of the PregMet randomised controlled trial. *Lancet Child Adolesc Health*. 2019;3(3):166–174.
- [66] Weng X, Liu F, Zhang H, et al. Genome-wide DNA methylation profiling in infants born to gestational diabetes mellitus. *Diabetes Res Clin Pract*. 2018;142:10–18.
- [67] Houshmand-Oeregaard A, Hansen NS, Hjort L, et al. Differential adipokine DNA methylation and gene expression in subcutaneous adipose tissue from adult offspring of women with diabetes in pregnancy. *Clin Epigenetics*. 2017;9:37.
- [68] Senner CE. The role of DNA methylation in mammalian development. *Reprod Biomed Online*. 2011;22(6):529–535.
- [69] Gibney ER, Nolan CM. Epigenetics and gene expression. *Heredity (Edinb)*. 2010;105(1):4–13.
- [70] Campanero MR, Armstrong MI, Flemington EK. CpG methylation as a mechanism for the regulation of E2F activity. *Proc Natl Acad Sci U S A*. 2000;97(12):6481–6486.
- [71] Comb M, Goodman HM. CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. *Nucleic Acids Res*. 1990;18(13):3975–3982.
- [72] Mancini DN, Singh SM, Archer TK, et al. Site-specific DNA methylation in the neurofibromatosis (NF1) promoter interferes with binding of CREB and SP1 transcription factors. *Oncogene*. 1999;18(28):4108–4119.
- [73] Yin H, Blanchard KL. DNA methylation represses the expression of the human erythropoietin gene by two different mechanisms. *Blood*. 2000;95(1):111–119.
- [74] Gu P, Le Menuet D, Chung AC, et al. Differential recruitment of methylated CpG binding domains by the orphan receptor GCNF initiates the repression and silencing of Oct4 expression. *Mol Cell Biol*. 2006;26(24):9471–9483.
- [75] Chen J, Meng Y, Zhou J, et al. Identifying candidate genes for Type 2 Diabetes Mellitus and obesity through gene expression profiling in multiple tissues or cells. *J Diabetes Res*. 2013;2013:970435.
- [76] Kokosar M, Benrick A, Perfiljev A, et al. A single bout of electroacupuncture remodels epigenetic and transcriptional changes in adipose tissue in polycystic ovary syndrome. *Sci Rep*. 2018;8(1):1878.
- [77] Brey CW, Nelder MP, Hailemariam T, et al. Kruppel-like family of transcription factors: an emerging new frontier in fat biology. *Int J Biol Sci*. 2009;5(6):622–636.
- [78] Roy D, Farabaugh KT, Wu J, et al. Coordinated transcriptional control of adipocyte triglyceride lipase (Atgl) by transcription factors Sp1 and peroxisome proliferator-activated receptor gamma (PPARGamma) during adipocyte differentiation. *J Biol Chem*. 2017;292(36):14827–14835.
- [79] Liao X, Sharma N, Kapadia F, et al. Kruppel-like factor 4 regulates macrophage polarization. *J Clin Invest*. 2011;121(7):2736–2749.
- [80] Yang SZ, Abdulkadir SA. Early growth response gene 1 modulates androgen receptor signaling in prostate carcinoma cells. *J Biol Chem*. 2003;278(41):39906–39911.
- [81] Gonzalez F, Kirwan JP, Rote NS, et al. Glucose ingestion stimulates atherothrombotic inflammation in polycystic ovary syndrome. *Am J Physiol Endocrinol Metab*. 2013;304(4):E375–83.
- [82] Yin M, Wang X, Yao G, et al. Transactivation of microRNA-320 by microRNA-383 regulates granulosa

- cell functions by targeting E2F1 and SF-1 proteins. *J Biol Chem.* **2014**;289(26):18239–18257.
- [83] Liu G, Sprenger C, Wu PJ, et al. MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand. *Oncotarget.* **2015**;6(1):288–304.
- [84] Das M, Djahanbakhch O, Hacıhanefioglu B, et al. Granulosa cell survival and proliferation are altered in polycystic ovary syndrome. *J Clin Endocrinol Metab.* **2008**;93(3):881–887.
- [85] Salvetti NR, Ortega HH, Veiga-Lopez A, et al. Developmental programming: impact of prenatal testosterone excess on ovarian cell proliferation and apoptotic factors in sheep1. *Biol Reprod.* **2012**;87(1). DOI:10.1095/biolreprod.112.100024
- [86] Babu KA, Rao KL, Kanakavalli MK, et al. CYP1A1, GSTM1 and GSTT1 genetic polymorphism is associated with susceptibility to polycystic ovaries in South Indian women. *Reprod Biomed Online.* **2004**;9(2):194–200.
- [87] Zandarashvili L, White MA, Esadze A, et al. Structural impact of complete CpG methylation within target DNA on specific complex formation of the inducible transcription factor Egr-1. *FEBS Lett.* **2015**;589(15):1748–1753.
- [88] Cole E, Brown TA, Pinkerton KE, et al. Perinatal exposure to environmental tobacco smoke is associated with changes in DNA methylation that precede the adult onset of lung disease in a mouse model. *Inhal Toxicol.* **2017**;29(10):435–442.
- [89] Kanwal R, Gupta K, Gupta S. Cancer epigenetics: an introduction. *Methods Mol Biol.* **2015**;1238:3–25.
- [90] Teruel M, Sawalha AH. Epigenetic variability in systemic lupus erythematosus: what we learned from genome-wide DNA methylation studies. *Curr Rheumatol Rep.* **2017**;19(6):32.
- [91] Li S, Zhu D, Duan H, et al. Differential DNA methylation patterns of polycystic ovarian syndrome in whole blood of Chinese women. *Oncotarget.* **2016**;8(13):20656–20666.
- [92] Sang Q, Zhang S, Zou S, et al. Quantitative analysis of follistatin (FST) promoter methylation in peripheral blood of patients with polycystic ovary syndrome. *Reprod Biomed Online.* **2013**;26(2):157–163.
- [93] Houde -A-A, Légaré C, Hould F-S, et al. Cross-tissue comparisons of leptin and adiponectin: DNA methylation profiles. *Adipocyte.* **2014**;3(2):132–140.
- [94] VA-m ER, Gomez-Viais YI, Garcia-Gomez E, et al. DNA methylation in the pathogenesis of polycystic ovary syndrome. *Reproduction.* **2019**;158(1):R27–R40.
- [95] Sliker RC, Bos SD, Goeman JJ, et al. Identification and systematic annotation of tissue-specific differentially methylated regions using the Illumina 450k array. *Epigenetics Chromatin.* **2013**;6(1):26.
- [96] Ma B, Wilker EH, Willis-Owen SA, et al. Predicting DNA methylation level across human tissues. *Nucleic Acids Res.* **2014**;42(6):3515–3528.